

Frederic Y Bois

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4384739/frederic-y-bois-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

137
papers

4,717
citations

40
h-index

64
g-index

150
ext. papers

5,346
ext. citations

4
avg, IF

5.37
L-index

#	Paper	IF	Citations
137	PBPK Modeling to Simulate the Fate of Compounds in Living Organisms.. <i>Methods in Molecular Biology</i> , 2022 , 2425, 29-56	1.4	
136	Multistate models of developmental toxicity: Application to valproic acid-induced malformations in the zebrafish embryo. <i>Toxicology and Applied Pharmacology</i> , 2021 , 414, 115424	4.6	2
135	Opening a debate on open-source modeling tools: Pouring fuel on fire versus extinguishing the flare of a healthy debate. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 , 10, 420-427	4.5	5
134	A Bayesian population physiologically based pharmacokinetic absorption modeling approach to support generic drug development: application to bupropion hydrochloride oral dosage forms. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021 , 48, 893-908	2.7	0
133	A generic PBTK model implemented in the MCRA platform: Predictive performance and uses in risk assessment of chemicals. <i>Food and Chemical Toxicology</i> , 2020 , 142, 111440	4.7	3
132	Development of a generic zebrafish embryo PBPK model and application to the developmental toxicity assessment of valproic acid analogs. <i>Reproductive Toxicology</i> , 2020 , 93, 219-229	3.4	7
131	Considerations and Caveats when Applying Global Sensitivity Analysis Methods to Physiologically Based Pharmacokinetic Models. <i>AAPS Journal</i> , 2020 , 22, 93	3.7	14
130	Well-tempered MCMC simulations for population pharmacokinetic models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2020 , 47, 543-559	2.7	2
129	Prediction of maternal and foetal exposures to perfluoroalkyl compounds in a Spanish birth cohort using toxicokinetic modelling. <i>Toxicology and Applied Pharmacology</i> , 2019 , 379, 114640	4.6	10
128	Quantitative AOP based teratogenicity prediction for mixtures of azole fungicides. <i>Computational Toxicology</i> , 2019 , 11, 72-81	3.1	8
127	Population pharmacokinetic reanalysis of a Diazepam PBPK model: a comparison of Stan and GNU MCSim. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2019 , 46, 173-192	2.7	6
126	Placental transfer of xenobiotics in pregnancy physiologically-based pharmacokinetic models: Structure and data. <i>Computational Toxicology</i> , 2019 , 12, 100111	3.1	14
125	Application of three approaches for quantitative AOP development to renal toxicity. <i>Computational Toxicology</i> , 2019 , 11, 1-13	3.1	23
124	Applying a Global Sensitivity Analysis Workflow to Improve the Computational Efficiencies in Physiologically-Based Pharmacokinetic Modeling. <i>Frontiers in Pharmacology</i> , 2018 , 9, 588	5.6	28
123	Investigation of Nrf2, AhR and ATF4 Activation in Toxicogenomic Databases. <i>Frontiers in Genetics</i> , 2018 , 9, 429	4.5	12
122	Multiscale modelling approaches for assessing cosmetic ingredients safety. <i>Toxicology</i> , 2017 , 392, 130-139	4.4	20
121	Ab initio chemical safety assessment: A workflow based on exposure considerations and non-animal methods. <i>Computational Toxicology</i> , 2017 , 4, 31-44	3.1	45

120	Adverse outcome pathways: opportunities, limitations and open questions. <i>Archives of Toxicology</i> , 2017 , 91, 3477-3505	5.8	174
119	High-Throughput Analysis of Ovarian Cycle Disruption by Mixtures of Aromatase Inhibitors. <i>Environmental Health Perspectives</i> , 2017 , 125, 077012	8.4	9
118	Graph_sampler: a simple tool for fully Bayesian analyses of DAG-models. <i>Computational Statistics</i> , 2017 , 32, 691-716	1	
117	Toxicokinetic models and related tools in environmental risk assessment of chemicals. <i>Science of the Total Environment</i> , 2017 , 578, 1-15	10.2	72
116	Herpes simplex virus type 2 (HSV-2) genital shedding in HSV-2-/HIV-1-co-infected women receiving effective combination antiretroviral therapy. <i>International Journal of STD and AIDS</i> , 2016 , 27, 178-85	1.4	4
115	Modeling Pharmacokinetics. <i>Methods in Molecular Biology</i> , 2016 , 1425, 37-62	1.4	4
114	The Next Generation of Risk Assessment Multi-Year Study-Highlights of Findings, Applications to Risk Assessment, and Future Directions. <i>Environmental Health Perspectives</i> , 2016 , 124, 1671-1682	8.4	59
113	Investigation of ifosfamide and chloroacetaldehyde renal toxicity through integration of in vitro liver-kidney microfluidic data and pharmacokinetic-system biology models. <i>Journal of Applied Toxicology</i> , 2016 , 36, 330-9	4.1	12
112	Comprehensive summary--Predict-IV: A systems toxicology approach to improve pharmaceutical drug safety testing. <i>Toxicology in Vitro</i> , 2015 , 30, 4-6	3.6	7
111	In vitro kinetics of amiodarone and its major metabolite in two human liver cell models after acute and repeated treatments. <i>Toxicology in Vitro</i> , 2015 , 30, 36-51	3.6	27
110	Probabilistic generation of random networks taking into account information on motifs occurrence. <i>Journal of Computational Biology</i> , 2015 , 22, 25-36	1.7	4
109	Joint modeling of survival and longitudinal non-survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group. <i>Statistics in Medicine</i> , 2015 , 34, 2181-95	2.3	79
108	Mechanism of cisplatin proximal tubule toxicity revealed by integrating transcriptomics, proteomics, metabolomics and biokinetics. <i>Toxicology in Vitro</i> , 2015 , 30, 117-27	3.6	78
107	Investigation of omeprazole and phenacetin first-pass metabolism in humans using a microscale bioreactor and pharmacokinetic models. <i>Biopharmaceutics and Drug Disposition</i> , 2015 , 36, 275-93	1.7	23
106	Responses to discussants of Joint modeling of survival and longitudinal non-survival data: current methods and issues. report of the DIA Bayesian joint modeling working group. <i>Statistics in Medicine</i> , 2015 , 34, 2202-3	2.3	5
105	Investigation of acetaminophen toxicity in HepG2/C3a microscale cultures using a system biology model of glutathione depletion. <i>Cell Biology and Toxicology</i> , 2015 , 31, 173-85	7.4	12
104	Quantitative in vitro to in vivo extrapolation of tissues toxicity. <i>Toxicology in Vitro</i> , 2015 , 30, 203-16	3.6	18
103	Development of an in vitro renal epithelial disease state model for xenobiotic toxicity testing. <i>Toxicology in Vitro</i> , 2015 , 30, 128-37	3.6	27

102	Understanding the biokinetics of ibuprofen after single and repeated treatments in rat and human in vitro liver cell systems. <i>Toxicology Letters</i> , 2015 , 233, 172-86	4.4	25
101	PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessment: recommendations from a joint EPAA--EURL ECVAM ADME workshop. <i>Regulatory Toxicology and Pharmacology</i> , 2014 , 68, 119-39	3.4	85
100	Integration of pharmacokinetic and NRF2 system biology models to describe reactive oxygen species production and subsequent glutathione depletion in liver microfluidic biochips after flutamide exposure. <i>Toxicology in Vitro</i> , 2014 , 28, 1230-41	3.6	13
99	First pass intestinal and liver metabolism of paracetamol in a microfluidic platform coupled with a mathematical modeling as a means of evaluating ADME processes in humans. <i>Biotechnology and Bioengineering</i> , 2014 , 111, 2027-40	4.9	53
98	Evaluation of a liver microfluidic biochip to predict in vivo clearances of seven drugs in rats. <i>Journal of Pharmaceutical Sciences</i> , 2014 , 103, 706-18	3.9	25
97	Systems biology modeling of omics data: effect of cyclosporine a on the Nrf2 pathway in human renal cells. <i>BMC Systems Biology</i> , 2014 , 8, 76	3.5	30
96	Extrapolating In Vitro Results to Predict Human Toxicity. <i>Methods in Pharmacology and Toxicology</i> , 2014 , 531-550	1.1	4
95	Computational pharmacokinetics at a crossroads. <i>In Silico Pharmacology</i> , 2013 , 1, 5	4.3	3
94	Toxicokinetics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches. <i>Toxicology in Vitro</i> , 2013 , 27, 1570-7	3.6	92
93	Multiscale modelling approach combining a kinetic model of glutathione metabolism with PBPK models of paracetamol and the potential glutathione-depletion biomarkers ophthalmic acid and 5-oxoproline in humans and rats. <i>Integrative Biology (United Kingdom)</i> , 2013 , 5, 877-88	3.7	30
92	Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. <i>Journal of Proteomics</i> , 2013 , 79, 180-94	3.9	138
91	Predict-IV project overview (EU grant 202222): non animal-based toxicity profiling by integrating toxic dynamics and biokinetics. <i>Toxicology Letters</i> , 2013 , 221, S7	4.4	2
90	Bayesian inference. <i>Methods in Molecular Biology</i> , 2013 , 930, 597-636	1.4	9
89	Addressing human variability in next-generation human health risk assessments of environmental chemicals. <i>Environmental Health Perspectives</i> , 2013 , 121, 23-31	8.4	87
88	Ignoring and adding errors do not improve the science. <i>Carcinogenesis</i> , 2013 , 34, 1689-91	4.6	1
87	Low-dose metabolism of benzene in humans: science and obfuscation. <i>Carcinogenesis</i> , 2013 , 34, 2-9	4.6	28
86	A computational model to predict rat ovarian steroid secretion from in vitro experiments with endocrine disruptors. <i>PLoS ONE</i> , 2013 , 8, e53891	3.7	12
85	Metabolomics in toxicology and preclinical research. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2013 , 30, 209-25	4.3	135

84	Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. <i>Toxicology and Applied Pharmacology</i> , 2012 , 259, 270-80	4.6	49
83	Population effects and variability. <i>Methods in Molecular Biology</i> , 2012 , 929, 521-81	1.4	5
82	Zonation related function and ubiquitination regulation in human hepatocellular carcinoma cells in dynamic vs. static culture conditions. <i>BMC Genomics</i> , 2012 , 13, 54	4.5	21
81	Population-Based Pharmacokinetic Modeling and Simulation 2012 , 1		1
80	Experimental Models in Nanotoxicology 2011 , 63-86		4
79	Estimating metabolic rate for butadiene at steady state using a Bayesian physiologically-based pharmacokinetic model. <i>Environmental and Ecological Statistics</i> , 2011 , 18, 131-146	2.2	2
78	Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010. <i>Archives of Toxicology</i> , 2011 , 85, 367-485	5.8	398
77	A mechanistic modeling framework for predicting metabolic interactions in complex mixtures. <i>Environmental Health Perspectives</i> , 2011 , 119, 1712-8	8.4	17
76	Physiologically based modelling and prediction of drug interactions. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010 , 106, 154-61	3.1	29
75	Occupational exposure to cobalt: a population toxicokinetic modeling approach validated by field results challenges the biological exposure index for urinary cobalt. <i>Journal of Occupational and Environmental Hygiene</i> , 2010 , 7, 54-62	2.9	6
74	PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. <i>Toxicology</i> , 2010 , 278, 256-67	4.4	137
73	GNU MCSim: Bayesian statistical inference for SBML-coded systems biology models. <i>Bioinformatics</i> , 2009 , 25, 1453-4	7.2	94
72	Stochasticity in physiologically based kinetics models: implications for cancer risk assessment. <i>Risk Analysis</i> , 2009 , 29, 1182-91	3.9	2
71	Development of a physiologically based kinetic model for 99m-technetium-labelled carbon nanoparticles inhaled by humans. <i>Inhalation Toxicology</i> , 2009 , 21, 1099-107	2.7	63
70	Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. <i>Regulatory Toxicology and Pharmacology</i> , 2008 , 50, 400-11	3.4	80
69	Quantifying heterogeneity in exposure-risk relationships using exhaled breath biomarkers for 1,3-butadiene exposures. <i>Journal of Breath Research</i> , 2008 , 2, 037018	3.1	2
68	Meeting report: moving upstream-evaluating adverse upstream end points for improved risk assessment and decision-making. <i>Environmental Health Perspectives</i> , 2008 , 116, 1568-75	8.4	56
67	Sequential updating of a new dynamic pharmacokinetic model for caffeine in premature neonates. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 59-74	6.2	5

66	Physiologically-based Kinetic Modelling (PBK Modelling): meeting the 3Rs agenda. The report and recommendations of ECVAM Workshop 63. <i>ATLA Alternatives To Laboratory Animals</i> , 2007 , 35, 661-71	2.1	46
65	Development of a physiologically based toxicokinetic model for butadiene and four major metabolites in humans: global sensitivity analysis for experimental design issues. <i>Chemico-Biological Interactions</i> , 2007 , 167, 168-83	5	27
64	Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation. <i>Toxicological Sciences</i> , 2007 , 99, 395-402	4.4	102
63	The application of a Bayesian approach to the analysis of a complex, mechanistically based model. <i>Journal of Biopharmaceutical Statistics</i> , 2007 , 17, 65-92	1.3	12
62	Toxicokinetics of inhaled trichloroethylene and tetrachloroethylene in humans at 1 ppm: empirical results and comparisons with previous studies. <i>Toxicological Sciences</i> , 2007 , 95, 23-36	4.4	35
61	An Approximate Method for Population Toxicokinetic Analysis With Aggregated Data. <i>Journal of Agricultural, Biological, and Environmental Statistics</i> , 2007 , 12, 346-363	1.9	4
60	Revisiting the population toxicokinetics of tetrachloroethylene. <i>Archives of Toxicology</i> , 2006 , 80, 382-5	5.8	10
59	Bayesian-Optimal Design via Interacting Particle Systems. <i>Journal of the American Statistical Association</i> , 2006 , 101, 773-785	2.8	58
58	Uncertainty Analysis: The Bayesian Approach. <i>Wiley Series in Probability and Statistics</i> , 2006 , 255-266	1.3	
57	Evaluation of antiangiogenic treatment effects on tumors microcirculation by Bayesian physiological pharmacokinetic modeling and magnetic resonance imaging. <i>Magnetic Resonance Imaging</i> , 2006 , 24, 1059-67	3.3	13
56	Pharmacokinetic-pharmacodynamic models for categorical toxicity data. <i>Regulatory Toxicology and Pharmacology</i> , 2005 , 41, 55-65	3.4	6
55	Use of a chemical probe to increase safety for human volunteers in toxicokinetic studies. <i>Risk Analysis</i> , 2005 , 25, 1559-71	3.9	6
54	Lumping in pharmacokinetics. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2005 , 32, 719-36	2.7	28
53	Propylene glycol monomethyl ether. A three-generation study of isomer beta effects on reproductive and developmental parameters in rats. <i>Toxicology and Industrial Health</i> , 2005 , 21, 33-40	1.8	3
52	Intratracheal instillation of cytoplasmic granules from Phleum pratense pollen induces IgE- and cell-mediated responses in the Brown Norway rat. <i>International Archives of Allergy and Immunology</i> , 2004 , 135, 24-9	3.7	12
51	Phleum pratense pollen starch granules induce humoral and cell-mediated immune responses in a rat model of allergy. <i>Clinical and Experimental Allergy</i> , 2004 , 34, 310-4	4.1	17
50	Extension of the isobolographic approach to interactions studies between more than two drugs: illustration with the convulsant interaction between pefloxacin, norfloxacin, and theophylline in rats. <i>Journal of Pharmaceutical Sciences</i> , 2004 , 93, 553-62	3.9	1
49	Environmental benzene exposure assessment for parent-child pairs in Rouen, France. <i>Science of the Total Environment</i> , 2003 , 308, 73-82	10.2	16

48	A Bayesian compartmental model for the evaluation of 1,3-butadiene metabolism. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2003 , 52, 291-305	1.5	17
47	Decrease in ovalbumin-induced pulmonary allergic response by benzaldehyde but not acetaldehyde exposure in a Guinea pig model. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2002 , 65, 995-1012	3.2	9
46	Assessing the reliability of PBPK models using data from methyl chloride-exposed, non-conjugating human subjects. <i>Archives of Toxicology</i> , 2001 , 75, 189-99	5.8	23
45	Évaluation des risques sanitaires environnementaux. <i>Revue Francaise Des Laboratoires</i> , 2001 , 2001, 59-63		
44	Genetic and dietary factors affecting human metabolism of 1,3-butadiene. <i>Chemico-Biological Interactions</i> , 2001 , 135-136, 407-28	5	12
43	Physiologically based pharmacokinetic modeling of inhalation exposure of humans to dichloromethane during moderate to heavy exercise. <i>Toxicological Sciences</i> , 2001 , 59, 209-18	4.4	28
42	Applications of population approaches in toxicology. <i>Toxicology Letters</i> , 2001 , 120, 385-94	4.4	26
41	Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics. <i>Environmental Health Perspectives</i> , 2000 , 108 Suppl 2, 307-16	8.4	64
40	Statistical analysis of Fisher et al. PBPK model of trichloroethylene kinetics. <i>Environmental Health Perspectives</i> , 2000 , 108 Suppl 2, 275-82	8.4	43
39	Bayesian analysis of an epidemiologic model of Plasmodium falciparum malaria infection in Ndiop, Senegal. <i>American Journal of Epidemiology</i> , 2000 , 152, 760-70	3.8	29
38	Statistical Issues in Toxicokinetic Modeling: A Bayesian Perspective. <i>Environmental Health Perspectives</i> , 2000 , 108, 883	8.4	16
37	Statistical issues in toxicokinetic modeling: a bayesian perspective. <i>Environmental Health Perspectives</i> , 2000 , 108 Suppl 5, 883-93	8.4	93
36	Optimal design for a study of butadiene toxicokinetics in humans. <i>Toxicological Sciences</i> , 1999 , 49, 213-24	4.4	29
35	Screening blood donations for hepatitis C in Central Africa: analysis of a risk- and cost-based decision tree. <i>Medical Decision Making</i> , 1999 , 19, 296-306	2.5	4
34	Analysis of PBPK models for risk characterization. <i>Annals of the New York Academy of Sciences</i> , 1999 , 895, 317-37	6.5	37
33	Development of new technique for risk assessment using physiologically based toxicokinetic models. <i>American Journal of Industrial Medicine</i> , 1999 , Suppl 1, 101-3	2.7	13
32	Development of new technique for risk assessment using physiologically based toxicokinetic models. <i>American Journal of Industrial Medicine</i> , 1999 , 36, 101-103	2.7	72
31	Considerations in the attainment of steady state: aggregate vs. individual assessment. <i>Pharmaceutical Research</i> , 1998 , 15, 1796-8	4.5	5

30	A group sequential approach to crossover trials for average bioequivalence. <i>Journal of Biopharmaceutical Statistics</i> , 1997 , 7, 87-96	1.3	12
29	Choice of student t - or Wilcoxon-based confidence intervals for assessment of average bioequivalence. <i>Journal of Biopharmaceutical Statistics</i> , 1997 , 7, 179-89	1.3	4
28	Analysis of Nonrandomly Censored Ordered Categorical Longitudinal Data from Analgesic Trials: Comment. <i>Journal of the American Statistical Association</i> , 1997 , 92, 1248	2.8	3
27	Dynamic modeling of bacteria in a pilot drinking-water distribution system. <i>Water Research</i> , 1997 , 31, 3146-3156	12.5	44
26	Benzene toxicokinetics in humans 1997 , 207-218		
25	A parametric approach to population bioequivalence. <i>Statistics in Medicine</i> , 1997 , 16, 441-54	2.3	12
24	MCSim: A Monte Carlo Simulation Program. <i>Journal of Statistical Software</i> , 1997 , 2,	7.3	40
23	Population Toxicokinetics of Benzene. <i>Environmental Health Perspectives</i> , 1996 , 104, 1405	8.4	12
22	Absorption rate vs. exposure: which is more useful for bioequivalence testing?. <i>Pharmaceutical Research</i> , 1996 , 13, 453-6	4.5	43
21	Population toxicokinetics of tetrachloroethylene. <i>Archives of Toxicology</i> , 1996 , 70, 347-55	5.8	69
20	Interspecies extrapolation of physiological pharmacokinetic parameter distributions. <i>Risk Analysis</i> , 1996 , 16, 741-54	3.9	18
19	Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior Distributions. <i>Journal of the American Statistical Association</i> , 1996 , 91, 1400-1412	2.8	249
18	Modeling human interindividual variability in metabolism and risk: the example of 4-aminobiphenyl. <i>Risk Analysis</i> , 1995 , 15, 205-13	3.9	37
17	Bacterial inoculum density and probability of para-nitrophenol biodegradability test response. <i>Ecotoxicology and Environmental Safety</i> , 1995 , 30, 274-82	7	39
16	Bioequivalence: performance of several measures of extent of absorption. <i>Pharmaceutical Research</i> , 1994 , 11, 715-22	4.5	53
15	Bioequivalence: performance of several measures of rate of absorption. <i>Pharmaceutical Research</i> , 1994 , 11, 966-74	4.5	61
14	Optimization issues in physiological toxicokinetic modeling: a case study with benzene. <i>Toxicology Letters</i> , 1993 , 69, 181-96	4.4	26
13	Pentachlorophenol carcinogenicity: extrapolation of risk from mice to humans. <i>Human and Experimental Toxicology</i> , 1993 , 12, 215-25	3.4	15

12	Assessment of pentachlorophenol exposure in humans using the clearance concept. <i>Human and Experimental Toxicology</i> , 1992 , 11, 17-26	3.4	15
11	An analysis of exposure rate effects for benzene using a physiologically based pharmacokinetic model. <i>Regulatory Toxicology and Pharmacology</i> , 1992 , 15, 122-36	3.4	24
10	Sensitivity analysis of a new model of carcinogenesis. <i>Journal of Theoretical Biology</i> , 1992 , 159, 361-75	2.3	4
9	Structure and parameterization of pharmacokinetic models: their impact on model predictions. <i>Risk Analysis</i> , 1992 , 12, 189-201	3.9	48
8	Interspecies extrapolation: a reexamination of acute toxicity data. <i>Risk Analysis</i> , 1992 , 12, 301-10	3.9	46
7	Pharmacokinetic concepts in assessing intake of pentachlorophenol by rats after exposure through drinking water. <i>Journal of Pharmaceutical Sciences</i> , 1992 , 81, 1113-8	3.9	4
6	Comparison of three physiologically based pharmacokinetic models of benzene disposition. <i>Toxicology and Applied Pharmacology</i> , 1991 , 110, 79-88	4.6	51
5	Modeling benzene pharmacokinetics across three sets of animal data: parametric sensitivity and risk implications. <i>Risk Analysis</i> , 1991 , 11, 641-54	3.9	54
4	Mechanisms of benzene carcinogenesis: application of a physiological model of benzene pharmacokinetics and metabolism. <i>Toxicology Letters</i> , 1991 , 56, 283-98	4.4	34
3	Precision and sensitivity of pharmacokinetic models for cancer risk assessment: tetrachloroethylene in mice, rats, and humans. <i>Toxicology and Applied Pharmacology</i> , 1990 , 102, 300-15	4.6	81
2	The Use of Pharmacokinetic Models in the Determination of Risks for Regulatory Purposes 1989 , 573-583		3
1	Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior Distributions		46